IL1B and breast carcinoma: In combination with Sora, inhibits cell growth inhibition in the S-phase and/or G2/M-phase for hepatocellular carcinomas Induction of cell cycle arrest in proliferating cells Impairment of cancer angiogenesis through inhibition of VEGF secretion in cancer cell lines Inhibition of MMP-3 protein activity in highly-invasive MDA-MB-231 breast cancer, reducing tumor invasion Interruption of cellular pathways (TNF-α, JAK3, IL-8, IL1B) responsible for inflammation